SC 006

Drug Profile

SC 006

Alternative Names: SC-006

Latest Information Update: 11 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AbbVie
  • Developer AbbVie; Stemcentrx
  • Class Antineoplastics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Colorectal cancer

Most Recent Events

  • 08 Mar 2017 Phase-I clinical trials in Colorectal cancer (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, In adults, In the elderly) in USA (IV)
  • 23 Jan 2017 AbbVie and Stemcentrx plan a phase I trial for Colorectal cancer (In adults, In the elderly, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in USA (NCT03035279)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top